Clinical Trials Browser

Completed × elsulfavirine × Other hematologic neoplasm × Clear all

NCT03625388 2023-09-22

Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Phase 2 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase